About Us
Based in New York City, Lexeo Therapeutics is a clinical-stage company dedicated to reshaping the path of genetic disease. Lexeo seeks to advance pioneering science to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. By taking aim at the underlying genetic cause of the devastating diseases we target, we seek to create substantial positive impact and reduce the overwhelming burdens placed on individuals receiving treatment, their caregivers, and healthcare systems. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and neurological diseases, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.